ASCO23: Patrick Wen, MD | Dana-Farber Cancer Institute

Glioma research: The first phase 3 clinical trial of a molecularly targeted therapy for low grade IDH-mutant glioma showed positive results and opens the door to new possibilities for patients. The INDIGO trial was presented during ASCO23 and co-led by Dana-Farber's Patrick Wen, MD. Press release here: https://www.dana-farber.org/newsroom/...